Long-term Efficacy and Safety of Cagrilintide s.c. 2.4 mg in Combination With Semaglutide s.c. 2.4 mg (CagriSema 2.4 mg/2.4 mg) Once Weekly Versus Placebo in Participants With Obesity
Latest Information Update: 24 Jan 2025
Price :
$35 *
At a glance
- Drugs Cagrilintide/semaglutide (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Sponsors Novo Nordisk
- 24 Jan 2025 New trial record